JNJ · Johnson & Johnson
Is JNJ setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on Johnson & Johnson, in one place.
Today's breakout radarIs JNJ setting up for a breakout?
Breakout Radar API →Not today. JNJ is not on today's radar: no tight base just under a resistance that has been tested again and again.
See the stocks that are setting up today →What are traders on X saying about JNJ?
Stock Sentiment API →Bulls: J&J raised its 2026 sales outlook to $101.2B as Tremfya sales jumped 68.3%, and the dividend has been increased for 64 consecutive years — from $0.37/share in 1996 to $5.14 in 2025. Oncology data were strong: JNJ-6143 (from the $3B Halda Therapeutics takeover in 2025) showed a 75% overall response rate in a Phase 1 readout at ESMO 2026, ERLEADA cut risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer, and Rybrevant Faspro plus Merck's Keytruda and carboplatin produced a 77% confirmed response rate in a 22-patient head-and-neck cancer subgroup (Phase 3 underway, investigational). The stock trades in the $161.50–$163.20 range with a 5-week EMA crossing above the 8-week SMA, though only 3 of 8 weeks were green.
Bears: JNJ reversed 2.21% off its intraday high of $272.36 to close at $266.35 — a bearish reversal ranked in the top 7% of its biggest ever, with the prior one in October 2026. Valuation is the core issue: JNJ costs 22.7x expected profits versus Merck at 15.7x.
Reading from Oct 28, 2026; each post classified by AI, weighted by engagement.
What is the news saying about JNJ?
News Sentiment API →No recent news reading for JNJ. The News Sentiment API reads today's headlines on any US stock.
Are JNJ insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
- Sold · Schmid Timothy$6.2M · Sep 2, 2026
- Sold · Schmid Timothy$3.0M · Sep 2, 2026
- Sold · Taubert Jennifer L$4.0M · Aug 17, 2026
- Sold · Duato Joaquin$26.7M · Aug 13, 2026
- Sold · Duato Joaquin$5.5M · Aug 13, 2026
How is Johnson & Johnson's business doing?
Financial Statements API →| Quarter ended | Revenue | vs year before | Net income | EPS |
|---|---|---|---|---|
| Jun 28, 2026 | $25.3B | +7% | $5.5B | $2.27 |
| Mar 29, 2026 | $24.1B | +10% | $5.2B | $2.14 |
| Sep 28, 2025 | $24.0B | +7% | $5.2B | $2.12 |
| Jun 29, 2025 | $23.7B | +6% | $5.5B | $2.29 |
From the company's SEC filings (10-Q and 10-K).
What does Johnson & Johnson expect?
Company Guidance API →- 2026 · adjusted operational earnings per share and adjusted earnings per share dilution · 8-K filed Jul 29, 2026
“Johnson & Johnson expects the transaction to dilute adjusted operational earnings per share and adjusted earnings per share by approximately $0.46 in 2026 and approximately $0.08 in 2027.”
- 2027 · adjusted operational earnings per share and adjusted earnings per share dilution · 8-K filed Jul 29, 2026
“Johnson & Johnson expects the transaction to dilute adjusted operational earnings per share and adjusted earnings per share by approximately $0.46 in 2026 and approximately $0.08 in 2027.”
- Full-year 2026 · adjusted operational sales growth · 8-K filed Jul 15, 2026
“Adjusted Operational Sales 1,2 Change vs. Prior Year / Mid-point 6.2% – 6.8% / 6.5%”
- Full-year 2026 · adjusted operational eps (diluted) · 8-K filed Jul 15, 2026
“Adjusted Operational EPS (Diluted) 2,4 / Mid-point Change vs. Prior Year / Mid-point $11.50 – $11.65 / $11.58”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.